I think IFF’s divestiture of its pharma solutions business is strategically smart — but the real lesson here is about trust. And that lesson applies whether you’re a multinational buying specialty chemicals or a mid-size manufacturer sourcing biocides for your coatings line.
Let me explain.
Why Transparency Matters More Than the Lowest Price
In our Q1 2024 quality audit, we reviewed 14 vendor tenders for specialty chemicals — commodity items used in industrial coatings. What jumped out wasn’t the price differences (which averaged 18% variation for near-identical specs), but what wasn’t listed. I’ve learned to ask “what’s NOT included” before asking “what’s the price.”
Take conformal coatings for electronics. One vendor listed a base price of $4.20 per liter — actually, $4.75 with required documentation. Their “lowest total cost” claim evaporated when we added:
- Rush delivery surcharge: 12%
- Batch certification (mandatory): $180/sample
- Storage requirements (temperature-controlled, minimum 6-month shelf life check)
That’s roughly 22% more than the upfront quote. The winning vendor listed all fees from day one — even though their base price was 9% higher. On a 50,000-liter annual order (which we didn't quite hit — more like 44,000 liters in 2024), the difference was about $138,000 in real costs.
The vendor who shows all the numbers first — even if the total looks higher — almost always costs less in the end.
The IFF Connection: Divestiture as Transparency Signal
When IFF completed its divestiture of pharma solutions, it wasn’t a price decision — it was a clarity decision. The pharma solutions division commanded an EBITDA multiple of 13x (according to their official release). That’s a strong valuation. But keeping it inside a specialty chemical portfolio creates complexity that buyers in both segments end up pricing into their bids — or worse, discovering post-contract.
I can only speak to domestic operations — if you’re dealing with international logistics for bulk orders, there are probably factors I’m not aware of. But here’s what I’ve seen: when a company simplifies its structure, the procurement process gets cleaner. Less ambiguity. Fewer “we need to check with the pharma division” delays. More straightforward pricing.
In 2022, we sourced sodium hydroxide (yes, it’s a chemical — a fairly basic one, actually) from a general chemical holdings company with a pharma division. The spec sheet kept referencing compliance documentation we didn’t need. That added two weeks to the review cycle. The same year, we switched to a focused specialty chemical supplier. Lead time dropped by 4 days, and the documentation was exactly what we needed — no more, no less.
To be fair, many pharma companies do need that level of certification. But if you’re making industrial coatings — not injectables — paying for pharma-grade documentation is a hidden cost you didn’t budget for.
What This Means for Your Procurement Process
I ran a blind test with our quality team last year: same chemical spec from two suppliers. Supplier A listed everything upfront (including $1,200 for batch-specific certification). Supplier B quoted low and added the certification fee in the final invoice (ugh — again).
72% of our team identified Supplier A as “more professional” without knowing the cost difference. The cost increase? Zero — because Supplier A’s base price was $0.08/kg higher, but they waived the certification fee on orders above 10,000 kg. Supplier B’s “savings” vanished when we hit 12,000 kg.
If I remember correctly, the overall cost difference was negligible — maybe 1.5% — but the trust gap was noticeable. That $0.08/kg difference? On a 50,000-unit order, it’s $4,000. But the hidden certification fees would have been $14,400. The math is straightforward.
Here’s the controversial part: I think the industry relies too much on “quote the base, hide the extras” as a sales tactic. It works for winning initial bids, but it fails in long-term relationships. IFF’s divestiture signals that clarity creates value.
Granted, this approach requires more upfront work from procurement teams. You need to know what you actually need before you ask. That’s easier said than done. But the savings — both in dollars and in trust — are real.
Responding to the Obvious Pushback
I get why some procurement managers prefer the “lowest quoted price” approach. Budgets are tight. List prices can be misleading if you know which fees to waive. But here’s the thing: if you’re a mid-size company without a dedicated sourcing team, the hidden costs are where you get burned.
In our 2024 audit of 200+ unique items (up from 150 in 2023 — we expanded the coating line), the vendors with transparent pricing had 34% higher customer satisfaction scores. That’s not a small bump. For our $18,000 annual project on specialty chemical samples, transparent pricing saved us exactly $3,240 in unplanned fees.
Your mileage may vary — if you’re buying bulk commodity chemicals with no spec variation, the calculation might be different. But for anything beyond the most basic procurement, I stand by this:
Transparency isn’t just an ethical choice — it’s a financial one.
IFF’s divestiture makes sense because they’re betting that specialization builds trust. And trust, in B2B procurement, is the most expensive line item — until you decide to stop hiding it.